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Abstract
Objective: The purpose of this study was to assess the safety and efﬁcacy of the ClariVein
w
system that employs mechanochemical ablation of the great saphenous vein (GSV).
Method: Patients eligible for ablation of the GSVunderwent micropuncture access with only
local anaesthesia to insert a 4 or 5 Fr sheath. The ClariVein
w catheter was placed through the
sheath, the wire was extruded, and the distal tip of the wire positioned 2 cm from the
saphenofemoral junction under ultrasound guidance. Catheter wire rotation was then
activated for 2–3 seconds at approximately 3500 rpm. With the wire rotating, infusion of
the sclerosant was started simultaneously with catheter pullback. The sclerosant used was
1.5% liquid sodium tetradecyl sulphate (Sotradecol
#, Bioniche Pharma Group, Geneva,
Switzerland).
Results: Thirty GSVs in 29 patients were treated. All patients have reached six-month follow-
up; the average number of postoperative days is 260. No adverse events have been reported.
The Primary Closure Rate is 96.7%.
Conclusion: Mechanochemical ablation appears to be safe and efﬁcacious. The ClariVein
w
technique eliminates the need for tumescent anaesthesia. The great majority of
incompetent GSVs can be treated with this technique.
Keywords: chronic venous disease; endovenous techniques; ultrasound-guided sclerotherapy;
varicose veins; venous insufﬁciency
Introduction
Over the last 10 years, numerous minimally inva-
sive methods have been utilized to treat great and
small saphenous vein incompetence.
1,2 Most of
these techniques involve percutaneous access,
local anaesthesia, some form of ablation, and short
operative times with relatively good safety and efﬁ-
cacy. The endothermal technologies require the use
of tumescent anaesthesia prior to energy delivery
and a generator to produce either laser or radiofre-
quency energy. Results have improved and compli-
cations have decreased as these techniques and
technologies have evolved.
3 In the modern era of
endothermal ablation (after 2006), efﬁcacy rates of
long-term closure are reported at levels well above
97%.
4,5 However, these methods currently still
require tumescent anaesthesia which can be a
source of patient procedural discomfort; further,
this portion of the procedure is the steepest part
of the physician learning curve.
Recent reports have evaluated ultrasound-guided
foam sclerotherapy of the great saphenous vein
(GSV).
6 While foam sclerotherapy does obviate the
necessity for tumescent anaesthesia, efﬁcacy rates
are lower than endothermal ablation and reported
complication rates are higher.
7,8 At present,
it cannot be stated that foam sclerotherapy is as efﬁ-
cacious as endothermal ablation.
A new mechanochemical device, (ClariVein
w,
Madison, CT, USA), was developed to minimize
the negative aspects of both endothermal ablation
and ultrasound-guided sclerotherapy (UGS) for
the treatment of saphenous incompetence, while
incorporating the beneﬁts of each. The advantages
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access, endovenous treatment, local anaesthesia
only (no tumescence anaesthesia) and a short pro-
cedure time. Since this system does not use
thermal energy, the potential for nerve damage is
minimized. The negative aspects eliminated by
the hybrid procedure are: the need for tumescence
anaesthesia required for endothermal ablation and
lower efﬁcacy rates for UGS. The mechanochemical
method achieves venous occlusion utilizing a wire
rotating within the lumen of the vein at 3500 rpm
which abrades (i.e. injures) the intima to allow for
better efﬁcacy of the sclerosant. A liquid sclerosant
(sodium tetradecyl sulphate) is concomitantly
infused through an opening close to the distal end
of the catheter near the rotating wire. These two
modalities, mechanical and chemical, achieve
venous occlusion results equal to endothermal
methods.
The entire device is for single use only and can be
inserted through a 4 or 5 Fr sheath utilizing local
insertion site anaesthesia only, without the need
for tumescence anaesthesia. The system includes
an infusion catheter, motor drive, stopcock and
syringe (Figure 1). This report describes the initial
human clinical trial in 30 limbs of mechanochemical
ablation to treat GSV incompetence.
Objectives
The purpose of this study was to assess the safety
and efﬁcacy of the ClariVein
w system which
employs mechanochemical ablation of the GSV.
Table 1 outlines the two primary objectives and
the three secondary objectives of this study. Also
given are the measures and measure deﬁnitions
used to assess the objectives.
Materials and methods
ClariVein
w is an infusion catheter system designed
to introduce physician-speciﬁed medications intra-
venously with simultaneous mechanical agitation
into a patient’s peripheral vasculature. Infusion is
through an opening at the distal end of the catheter.
Fluid delivery is enhanced by the use of a rotating
dispersion wire to mix the infused ﬂuid in the
target vein and onto the vessel wall, as well as,
abrade the venous intima. The dispersion wire
extends through the catheter lumen. It is connected
to an interface Cartridge Unit for connection to the
9 V DC battery motorized Handle Unit on the
proximal end, which controls wire rotation. The
Handle Unit also provides a grip and syringe
holder to facilitate physician-controlled infusion.
After purging with saline to ensure a closed
system and prior to drug infusion, the wire plus
catheter sheath is inserted into the vein percuta-
neously. The catheter sheath is retracted to expose
the wire tip, which is positioned 2 cm from the
saphenofemoral junction. The catheter motor is
turned ON and, with the wire rotating and sclero-
sant infusing, the catheter is pulled down the vein
at a rate of approximately 1–2 mm per second.
The wire that passes through the catheter is 304 V
stainless steel; the conﬁguration of the dispersion
tip has been optimized for mechanochemical vein
ablation. The wire is steerable and therefore will
transverse most tortuous GSV segments.
Protocol
Assessment
Patients underwent examination by a senior venous
surgeon and ultrasound evaluation, and if deemed
eligible for thermal ablation (laser or radiofre-
quency) of the GSV were considered for this Insti-
tutional Review Board (IRB) approved protocol.
The assessment included evaluation of GSV reﬂux,
Venous Clinical Severity Score (VCSS),
9 CEAP




Reﬂux was determined at the saphenofemoral
junction in the standing position using the Valsalva
manoeuvre or manual distal compression with
rapid release. Reﬂux as documented by ultrasound
extending for 0.5 seconds or longer was considered
signiﬁcant. CEAP Class 1 patients were excluded.
Other exclusion criteria were the same as those for
endothermal ablation and included: acute deep
vein thrombosis (DVT), immobility, anticoagulation
and GSV diameters . 12 mm. Figure 1 Picture of the ClariVein
w device
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At the time of the procedure, patients were placed in
the reversed Trendelenberg position on a procedure
table. Repeat ultrasound examination was performed
to conﬁrm the important anatomic and haemo-
dynamic parameters. This included imaging of the
target vein for access, the saphenofemoral junction,
perforators, tributaries, diameter and treatment
length.
With the patient in the reversed Trendelenburg
position, micropuncture access was obtained. Only
local anaesthesia was used to insert the 4 or 5 Fr
sheath. The ClariVein
w catheter was placed
through the sheath, the wire was extruded and the
distal tip of the wire positioned 2 cm from the
saphenofemoral junction under ultrasound gui-
dance. The patient was then rotated to a ﬂat position
for the remainder of the procedure. Catheter wire
rotation was ﬁrst activated for 2–3 seconds at the
highest speed setting (approximately 3500 rpm).
This creates venospasm which minimizes forward
ﬂow into the common femoral vein. With the wire
continuing to rotate, infusion of the sclerosant was
started simultaneously with catheter pullback. The
sclerosant used was 1.5% liquid sodium tetradecyl
sulphate (Sotradecol
#). For this study all treated
veins received 12 cc of 1.5% sclerosant. The sclero-
sant volume was independent of vein diameter
and treatment length. The pullback rate was
between 1.0 and 2.0 mm/second. No other conco-
mitant procedures were performed (i.e. microphle-
bectomy or perforator ablation) so as to have the
evaluation of safety and efﬁcacy wholly dependent
on mechanochemical ablation. All entered subjects
underwent a completed procedure.
Postprocedure
When the catheter had traversed the entire treatment
length and had been removed, the surgical team
checked for GSV occlusion and patency of the
common femoral vein using ultrasound. A 4′ and 6′
compression bandage was applied to the treated
limb from the foot to the groin. This remained
in place for 24 hours. The patients then applied a
15–20 mmHg thigh-high compression stocking con-
tinuously for the next 48 hours, except whilst shower-
ing. They then utilized the compression stocking only
during the day for the next 10 days. Patient activity
was not restricted. All forms of reasonable exercise
were approved from the ﬁrst postprocedure day.
The patients were instructed to take only over-the-
counter medication for discomfort.
Follow-up
Follow-up visits at one week, one month, three
months and six months were performed. At each
visit an ultrasound study and clinical exam was
performed. Occlusion and vein wall changes were
documented (Figures 2 and 3).
Results
Using the protocol described above, a single experi-
enced venous surgeon treated 30 GSVs in 29
patients during the period 20 February 2009 and
17 July 2009 (+5 months). The average age of the
Table 1 Primary and Secondary objectives
Objective Objective deﬁnition Measures Measure deﬁnition
Primary
1 Determine overall safety of the
ClariVein
w procedure
Adverse events and serious
adverse events. This includes all
clinical complications
Standard deﬁnitions of adverse events and serious
advance events as deﬁned by the FDA were used
during the six-month postprocedure period
Primary




Primary Closure Rate at six
months
Based on duplex ultrasound evaluation the closure of
the treated vein is determined. Primary Closure Rate
is calculated by dividing the number of closed veins
at six months by the total veins treated (%).
A continuous segment of 5 cm in length of treated
vein is considered an open vein
Secondary
1 Measures of pain associated with the
ClariVein
w procedure and during
follow-up
Pain levels reported by the patient These data are gathered during the procedure and
at all visits during the six-month postprocedure
period
Secondary
2 Listing of pain therapy during the
ClariVein
w procedure and medi-
cation required during follow-up
Monitoring of medication
required for pain
Monitoring of medication, dose, and timing for pain
during the procedure and during the six-month
postprocedure period
Secondary
3 Identify eccymosis secondary to the
ClariVein
w procedure
Degree of eccymosis as reported
by the clinical staff using a
simple scale
These data are gathered during the procedure and at
all visits during the six-month postprocedure period.
Possible answers ranged from No Eccymosis to
Eccymosis over entire Length with Extension
FDA, Federal Drug Administration
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Sixty percent of the subjects were women. The abla-
tion procedures were limited to the GSV. In all cases
comprehensive lower-extremity venous duplex
examinations were performed to determine
venous insufﬁciency and indications for the pro-
cedure. GSV reﬂux was carefully measured in the
standing position. In all cases GSV reﬂux time was
.2 seconds with a range of 2–5 seconds. In 47%
of the operated limbs, veins other than the GSV,
Figure 2 Ultrasound of closed GSV at one-week (no ﬂow and no vein wall retraction).
GSV, great saphenous vein
Figure 3 Ultrasound of closed GSV at 12 months (no ﬂow and complete vein wall retraction).
GSV, great saphenous vein
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deep system, other superﬁcial veins and perforating
veins.
The average VCSS score was 4.5 with a range of
1–14. In all cases signiﬁcant varicose veins were
present. The six-point CEAP classiﬁcation ranged
from 2–4. In our series 77% were in Class 2 (vari-
cose veins), 7% in Class 3 (varicose veins and
oedema) and 16% in Class 4a (varicose veins with
skin changes).
In our series the average diameter of the treated
GSV was 8.1 mm with a range of 5.5–13 mm. The
average treatment length was 37.5 cm with a
range of 24–47 cm. The total procedure time aver-
aged 14 minutes. The average total time for the
ablation portion of the procedure was nine
minutes with a range of 6–17 minutes. The catheter
was in the active treatment mode, including pull-
back for an average of ﬁve minutes and 15
seconds. The range was three minutes and 40
seconds to six minutes and 45 seconds (pullback
rate 1–2 mm/second). For this series no other vein
segments were treated and no secondary treatment
was administered. During the procedure patients
did not complain of pain. Three minor thigh eccy-
mosis were observed at levels where the rotating
wire may have caught on a valve cusp or vein
wall. No DVT nerve or skin injury occurred. No
patient complained of parathesia, hypothesia or
motor dysfunction on clinical examination.
To date, there are no patients lost to follow up. All
patients have reached the six-month follow-up
point. The average follow-up is 260 days with a
range of 140–510 days. At this point only one vein
has recanalized. This was the ﬁrst case in this
series. While there is ultrasound evidence of recana-
lization, the treated vein is not reﬂuxing. The reca-
nalization occurred between the one-week and
one-month visits. This corresponds to a Primary
Closure Rate of 96.7% at 260 days. Thus, any vein
with a successful outcome at one-month has
remained occluded at the six-month follow-up visit.
Discussion
The ﬁrst primary objective was to determine overall
safety of the ClariVein
w procedure. Most investi-
gators have found that the vast majority of
adverse events associated with superﬁcial vein
closure occur at the procedure or within the ﬁrst
30 days after the procedure. An exception is recana-
lization of the treated segment. Our ﬁrst primary
objective was to assess safety of the procedure.
A total of 30 veins were treated in 29 patients.
No adverse events or serious adverse events were
recorded. Our deﬁnition of adverse event included
new events not seen before the index surgical pro-
cedure, a pre-existing event that recurred with
increased intensity or increased frequency sub-
sequent to the index procedure and events which
were present at the time of study entrance which
became exacerbated. Our deﬁnition of serious
adverse events included death, life-threatening
events, any event which is disabling or incapacitat-
ing, events requiring prolonged hospitalization, any
cancer and clinical chemistry results that are con-
sidered a major clinical concern. With no adverse
events our ﬁndings suggest that the ClariVein
w pro-
cedure is safe based on up to six months of
follow-up.
Our second primary objective was to determine
efﬁcacy. The measure we elected to use was
Primary Closure Rate based on ultrasound. In our
series, 29 of 30 veins are closed corresponding to a
Primary Closure Rate of 96.7% at a mean follow-up
of 260 days. Since this rate is comparable to the best
published results for endovenous laser (EVL) and
radiofrequency at the same follow-up, our assess-
ment suggests the procedure is efﬁcacious based
on six months of follow-up.
The ﬁrst and second secondary objective are
associated with pain and required medication
during the procedure and at follow-up. During
the procedures (30 veins in 29 patients), no patient
complained of pain and no medication in addition
to the 1 cc injection at the cannulation site was
requested. The third secondary objective is ecchy-
mosis (bruising) secondary to the ClariVein
w pro-
cedure. Again since tumescent anaesthesia is not
required, bruising was not noted in our patients.
Three patients did have minor upper-thigh ecchy-
mosis perhaps due to the rotating wire catching
on the side branch or valve cusp. A gentle tension
is required for release; this may cause a small tear
in the vein wall.
Tumescent anaesthesia obviates the transfer of
thermal energy to non-target tissues by creating a
heat sink; further, it mechanically reduces the
luminal diameter of the vein wall to better contact
the indwelling items such as laser ﬁbre or radiofre-
quency catheter. However, its placement requires
multiple patient needle-sticks. Tumescent infusion
is the steepest part of the learning curve for new
practitioners. It is also the longest part of a short
procedure; eliminating tumescent infusion is a
desirable goal. Furthermore, thermal ablation
(laser or radiofrequency) requires the acquisition
of a generator and may be associated with a signiﬁ-
cant degree of postoperative pain and bruising.
3
It should be acknowledged that the closure rates
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advances in radiofrequency catheters have reduced
pain and bruising, and increased wavelengths in
endovenous lasers have also reduced postoperative
pain and bruising. The risk of thermal injury to
nerve, muscle or skin is minimized.
However, the generator cost and the requirement
for tumescent anaesthesia remain negative issues
for this technology. ClariVein
w does not require a
generator or the use of tumescent anaesthesia.
The risk of thermal injury to nerve, skin or muscle
is eliminated. The GSV can be treated over its full
length if clinically indicated without concern for
nerve injury. This can also be extrapolated to treat-
ment of the small saphenous vein.
The initial experience in patients described above
using ClariVein
w clearly has been valuable on
several fronts. While only 30 GSVs were treated,
the age and age range of the patients and their pre-
senting proﬁles mimic studies using other endove-
nous modalities. Actually, this study had a higher
percentage of men than the average superﬁcial
venous ablation trial. The patients in this study
were clear candidates for GSV treatment; however,
they did not have advanced disease. The average
VCSS was 4.5% and 77% of subjects were in CEAP
Class 2. The average GSV supine diameter at the
saphenofemoral junction was 8.1 mm (5.5–
13 mm). This is the vein size published for many
contemporary trials. Our average treatment length
was 37.5 cm (24–47 cm) and is also consistent
with current trial results.
Conclusions
Mechanochemical ablation appears to be safe and
efﬁcacious. The technique eliminates the need for
tumescent anaesthesia, a goal that both radiofre-
quency and laser technologies are currently explor-
ing.
11 The elimination of tumescent infusion
decreases patient discomfort, shortens the physi-
cian learning curve and shortens procedure time
by getting rid of the longest part of the relatively
short procedure of endovenous ablation.
The great majority of incompetent GSVs can be
treated with this technique. Veins which may not
be candidates for mechanochemical ablation
include those with previous thrombophlebitis
which have recanalized and are incompetent.
A few of those were attempted after the clinical
trial. The rotating wire was found to tangle on the
synechiae and trabeculae of the recanalized vein
which limits mechanical treatment.
Follow-up in the initial 30 patients and sub-
sequent patients will continue. In addition, a Clari-
Vein
w registry has been initiated. Those patients
treated by properly-trained physicians will be
entered.
In conclusion, mechanochemical ablation utiliz-
ing the ClariVein
w device has good safety and
appears to have good efﬁcacy; the method should
be considered as another viable alternative for the
management of saphenous incompetence.
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